Publications by authors named "Beatriz Guijarro-Albaladejo"
Article Synopsis
- CAR therapy targeting BCMA is being improved with the new anti-BCMA CAR called CARTemis-1, which aims to be more effective against multiple myeloma, addressing the challenges of current treatments that lack sustained effectiveness.
- The study demonstrated that the longer version of CARTemis-1 showed better cancer-killing ability and confirmed that certain manufacturing conditions, like specific cytokines, enhance CAR-T cell quality and effectiveness.
- CARTemis-1 was found to be effective without being inhibited by soluble BCMA, and it successfully met regulatory standards for production while exhibiting strong antitumor effects in both lab and live models.
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor prognosis despite the advent of novel therapies. Consequently, a major need exists for new therapeutic options, particularly for patients with relapsed/refractory (R/R) AML. In recent years, it has been possible to individualize the treatment of a subgroup of patients, particularly with the emergence of multiple targeted therapies.
View Article and Find Full Text PDFMonitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies.
Front Immunol
May 2023
Purpose: CAR-T cell therapy has proven to be a disruptive treatment in the hematology field, however, less than 50% of patients maintain long-term response and early predictors of outcome are still inconsistently defined. Here, we aimed to optimize the detection of CD19 CAR-T cells in blood and to identify phenotypic features as early biomarkers associated with toxicity and outcomes.
Experimental Design: In this study, monitoring by flow cytometry and digital PCR (dPCR), and immunophenotypic characterization of circulating CAR-T cells from 48 patients treated with Tisa-cel or Axi-cel was performed.
In spite of the enormous potential of CRISPR/Cas in basic and applied science, the levels of undesired genomic modifications cells still remain mostly unknown and controversial. Nowadays, the efficiency and specificity of the cuts generated by CRISPR/Cas is the main concern. However, there are also other potential drawbacks when DNA donors are used for gene repair or gene knock-ins.
View Article and Find Full Text PDFLipoprotein receptor-related protein 10 (LRP10) has been proposed as a novel causative gene for autosomal dominant Parkinson's disease (PD), and the c.919T>A (p.Tyr307Asn) variant has been identified as possibly involved in the development of familial PD and PD with dementia.
View Article and Find Full Text PDF